カテゴリー： LP Information, 世界, 医療/バイオ

局所分節性糸球体硬化症（FSGS）治療のグローバル市場予測2023-2029

◆英語タイトル：Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Growth 2023-2029

LP Informationが発行した調査報告書（LP23OT8921）◆商品コード：LP23OT8921
◆発行会社（リサーチ会社）：LP Information
◆発行日：2023年10月
◆ページ数：100
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥549,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥823,500見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,098,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LP Informationの最新刊調査レポート「局所分節性糸球体硬化症（FSGS）治療のグローバル市場」は、過去の販売実績から2022年の世界の局所分節性糸球体硬化症（FSGS）治療の総販売量を検討し、2023年から2029年の予測される局所分節性糸球体硬化症（FSGS）治療の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の局所分節性糸球体硬化症（FSGS）治療の市場規模を掲載し、XXX百万米ドル規模の世界の局所分節性糸球体硬化症（FSGS）治療市場の詳細な分析を提供します。本インサイトレポートは、世界の局所分節性糸球体硬化症（FSGS）治療業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の局所分節性糸球体硬化症（FSGS）治療市場における各社の独自のポジションをより深く理解するために、局所分節性糸球体硬化症（FSGS）治療製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の局所分節性糸球体硬化症（FSGS）治療市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。局所分節性糸球体硬化症（FSGS）治療の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。局所分節性糸球体硬化症（FSGS）治療の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。局所分節性糸球体硬化症（FSGS）治療のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

局所分節性糸球体硬化症（FSGS）治療の世界主要メーカーとしては、Competition Deep Dive、 Beckman Coulter Inc.、 Baxter International Inc.、 ChemoCentryx Inc.、 Dimerix Ltd、 Medtronic PLC、 Pfizer Inc.、 Mylan N.V.、 Amgen Inc.、 AstraZeneca plcなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の局所分節性糸球体硬化症（FSGS）治療市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場セグメンテーション】

この調査では局所分節性糸球体硬化症（FSGS）治療市場をセグメンテーションし、種類別 (薬物療法、透析、腎移植)、用途別 (プライマリFSGS、セカンダリFSGS)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：薬物療法、透析、腎移植

・用途別区分：プライマリFSGS、セカンダリFSGS

・地域別区分
南北アメリカ（米国、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の局所分節性糸球体硬化症（FSGS）治療市場の10年間の市場状況・展望は？
・世界および地域別に見た局所分節性糸球体硬化症（FSGS）治療市場成長の要因は何か？
・局所分節性糸球体硬化症（FSGS）治療の市場機会はエンドマーケットの規模によってどのように変化するのか？
・局所分節性糸球体硬化症（FSGS）治療のタイプ別、用途別の内訳は？
・新型コロナウイルスとロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：局所分節性糸球体硬化症（FSGS）治療の年間販売量2018-2029、地域別現状・将来分析
・局所分節性糸球体硬化症（FSGS）治療の種類別セグメント：薬物療法、透析、腎移植
・局所分節性糸球体硬化症（FSGS）治療の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・局所分節性糸球体硬化症（FSGS）治療の用途別セグメント：プライマリFSGS、セカンダリFSGS
・局所分節性糸球体硬化症（FSGS）治療の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の局所分節性糸球体硬化症（FSGS）治療市場
・企業別のグローバル局所分節性糸球体硬化症（FSGS）治療市場データ：2018-2023年の年間販売量、市場シェア
・企業別の局所分節性糸球体硬化症（FSGS）治療の年間売上：2018-2023年の売上、市場シェア
・企業別の局所分節性糸球体硬化症（FSGS）治療販売価格
・主要企業の局所分節性糸球体硬化症（FSGS）治療生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

局所分節性糸球体硬化症（FSGS）治療の地域別レビュー
・地域別の局所分節性糸球体硬化症（FSGS）治療市場規模2018-2023：年間販売量、売上
・主要国別の局所分節性糸球体硬化症（FSGS）治療市場規模2018-2023：年間販売量、売上
・南北アメリカの局所分節性糸球体硬化症（FSGS）治療販売の成長
・アジア太平洋の局所分節性糸球体硬化症（FSGS）治療販売の成長
・ヨーロッパの局所分節性糸球体硬化症（FSGS）治療販売の成長
・中東・アフリカの局所分節性糸球体硬化症（FSGS）治療販売の成長

南北アメリカ市場
・南北アメリカの国別の局所分節性糸球体硬化症（FSGS）治療販売量、売上（2018-2023）
・南北アメリカの局所分節性糸球体硬化症（FSGS）治療の種類別販売量
・南北アメリカの局所分節性糸球体硬化症（FSGS）治療の用途別販売量
・米国市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の局所分節性糸球体硬化症（FSGS）治療販売量、売上（2018-2023）
・アジア太平洋の局所分節性糸球体硬化症（FSGS）治療の種類別販売量
・アジア太平洋の局所分節性糸球体硬化症（FSGS）治療の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の局所分節性糸球体硬化症（FSGS）治療販売量、売上（2018-2023）
・ヨーロッパの局所分節性糸球体硬化症（FSGS）治療の種類別販売量
・ヨーロッパの局所分節性糸球体硬化症（FSGS）治療の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の局所分節性糸球体硬化症（FSGS）治療販売量、売上（2018-2023）
・中東・アフリカの局所分節性糸球体硬化症（FSGS）治療の種類別販売量
・中東・アフリカの局所分節性糸球体硬化症（FSGS）治療の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・局所分節性糸球体硬化症（FSGS）治療の製造コスト構造分析
・局所分節性糸球体硬化症（FSGS）治療の製造プロセス分析
・局所分節性糸球体硬化症（FSGS）治療の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・局所分節性糸球体硬化症（FSGS）治療の主要なグローバル販売業者
・局所分節性糸球体硬化症（FSGS）治療の主要なグローバル顧客

地域別の局所分節性糸球体硬化症（FSGS）治療市場予測レビュー
・地域別の局所分節性糸球体硬化症（FSGS）治療市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・局所分節性糸球体硬化症（FSGS）治療の種類別市場規模予測
・局所分節性糸球体硬化症（FSGS）治療の用途別市場規模予測

主要企業分析
Competition Deep Dive、 Beckman Coulter Inc.、 Baxter International Inc.、 ChemoCentryx Inc.、 Dimerix Ltd、 Medtronic PLC、 Pfizer Inc.、 Mylan N.V.、 Amgen Inc.、 AstraZeneca plc
・企業情報
・局所分節性糸球体硬化症（FSGS）治療製品
・局所分節性糸球体硬化症（FSGS）治療販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Focal Segmental Glomerulosclerosis (FSGS) Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Focal Segmental Glomerulosclerosis (FSGS) Treatment by Country/Region, 2018, 2022 & 2029
2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Segment by Type
2.2.1 Drug Therapy
2.2.2 Dialysis
2.2.3 Kidney Transplant
2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type
2.3.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sale Price by Type (2018-2023)
2.4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Segment by Application
2.4.1 Primary FSGS
2.4.2 Secondary FSGS
2.5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application
2.5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sale Price by Application (2018-2023)
3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment by Company
3.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Breakdown Data by Company
3.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Company (2018-2023)
3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Company (2018-2023)
3.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sale Price by Company
3.4 Key Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Location Distribution
3.4.2 Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Focal Segmental Glomerulosclerosis (FSGS) Treatment by Geographic Region
4.1 World Historic Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Growth
4.4 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Growth
4.5 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Growth
4.6 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Growth
5 Americas
5.1 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Country
5.1.1 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Country (2018-2023)
5.1.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Country (2018-2023)
5.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type
5.3 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Region
6.1.1 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Region (2018-2023)
6.1.2 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Region (2018-2023)
6.2 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type
6.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment by Country
7.1.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Country (2018-2023)
7.1.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Country (2018-2023)
7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment by Country
8.1.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type
8.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Focal Segmental Glomerulosclerosis (FSGS) Treatment
10.3 Manufacturing Process Analysis of Focal Segmental Glomerulosclerosis (FSGS) Treatment
10.4 Industry Chain Structure of Focal Segmental Glomerulosclerosis (FSGS) Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Distributors
11.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Customer
12 World Forecast Review for Focal Segmental Glomerulosclerosis (FSGS) Treatment by Geographic Region
12.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Forecast by Region
12.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Region (2024-2029)
12.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Type
12.7 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Application
13 Key Players Analysis
13.1 Competition Deep Dive
13.1.1 Competition Deep Dive Company Information
13.1.2 Competition Deep Dive Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.1.3 Competition Deep Dive Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Competition Deep Dive Main Business Overview
13.1.5 Competition Deep Dive Latest Developments
13.2 Beckman Coulter Inc.
13.2.1 Beckman Coulter Inc. Company Information
13.2.2 Beckman Coulter Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.2.3 Beckman Coulter Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Beckman Coulter Inc. Main Business Overview
13.2.5 Beckman Coulter Inc. Latest Developments
13.3 Baxter International Inc.
13.3.1 Baxter International Inc. Company Information
13.3.2 Baxter International Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.3.3 Baxter International Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Baxter International Inc. Main Business Overview
13.3.5 Baxter International Inc. Latest Developments
13.4 ChemoCentryx Inc.
13.4.1 ChemoCentryx Inc. Company Information
13.4.2 ChemoCentryx Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.4.3 ChemoCentryx Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 ChemoCentryx Inc. Main Business Overview
13.4.5 ChemoCentryx Inc. Latest Developments
13.5 Dimerix Ltd
13.5.1 Dimerix Ltd Company Information
13.5.2 Dimerix Ltd Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.5.3 Dimerix Ltd Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Dimerix Ltd Main Business Overview
13.5.5 Dimerix Ltd Latest Developments
13.6 Medtronic PLC
13.6.1 Medtronic PLC Company Information
13.6.2 Medtronic PLC Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.6.3 Medtronic PLC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Medtronic PLC Main Business Overview
13.6.5 Medtronic PLC Latest Developments
13.7 Pfizer Inc.
13.7.1 Pfizer Inc. Company Information
13.7.2 Pfizer Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.7.3 Pfizer Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer Inc. Main Business Overview
13.7.5 Pfizer Inc. Latest Developments
13.8 Mylan N.V.
13.8.1 Mylan N.V. Company Information
13.8.2 Mylan N.V. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.8.3 Mylan N.V. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Mylan N.V. Main Business Overview
13.8.5 Mylan N.V. Latest Developments
13.9 Amgen Inc.
13.9.1 Amgen Inc. Company Information
13.9.2 Amgen Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.9.3 Amgen Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Amgen Inc. Main Business Overview
13.9.5 Amgen Inc. Latest Developments
13.10 AstraZeneca plc
13.10.1 AstraZeneca plc Company Information
13.10.2 AstraZeneca plc Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
13.10.3 AstraZeneca plc Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 AstraZeneca plc Main Business Overview
13.10.5 AstraZeneca plc Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Focal Segmental Glomerulosclerosis (FSGS) Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Drug Therapy
Table 4. Major Players of Dialysis
Table 5. Major Players of Kidney Transplant
Table 6. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type (2018-2023) & (K Units)
Table 7. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Type (2018-2023)
Table 8. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Type (2018-2023) & ($ million)
Table 9. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Type (2018-2023)
Table 10. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application (2018-2023) & (K Units)
Table 12. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Application (2018-2023)
Table 13. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Application (2018-2023)
Table 14. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Application (2018-2023)
Table 15. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Company (2018-2023) & (K Units)
Table 17. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Company (2018-2023)
Table 18. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Company (2018-2023)
Table 20. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Treatment Producing Area Distribution and Sales Area
Table 22. Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Products Offered
Table 23. Focal Segmental Glomerulosclerosis (FSGS) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share Geographic Region (2018-2023)
Table 28. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country/Region (2018-2023)
Table 32. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Country (2018-2023) & (K Units)
Table 35. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country (2018-2023)
Table 36. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Country (2018-2023)
Table 38. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type (2018-2023) & (K Units)
Table 39. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application (2018-2023) & (K Units)
Table 40. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Region (2018-2023) & (K Units)
Table 41. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Region (2018-2023)
Table 42. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Region (2018-2023)
Table 44. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type (2018-2023) & (K Units)
Table 45. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application (2018-2023) & (K Units)
Table 46. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Country (2018-2023) & (K Units)
Table 47. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country (2018-2023)
Table 48. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Country (2018-2023)
Table 50. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type (2018-2023) & (K Units)
Table 51. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Focal Segmental Glomerulosclerosis (FSGS) Treatment
Table 59. Key Market Challenges & Risks of Focal Segmental Glomerulosclerosis (FSGS) Treatment
Table 60. Key Industry Trends of Focal Segmental Glomerulosclerosis (FSGS) Treatment
Table 61. Focal Segmental Glomerulosclerosis (FSGS) Treatment Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Focal Segmental Glomerulosclerosis (FSGS) Treatment Distributors List
Table 64. Focal Segmental Glomerulosclerosis (FSGS) Treatment Customer List
Table 65. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Competition Deep Dive Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 80. Competition Deep Dive Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 81. Competition Deep Dive Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Competition Deep Dive Main Business
Table 83. Competition Deep Dive Latest Developments
Table 84. Beckman Coulter Inc. Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 85. Beckman Coulter Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 86. Beckman Coulter Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Beckman Coulter Inc. Main Business
Table 88. Beckman Coulter Inc. Latest Developments
Table 89. Baxter International Inc. Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 90. Baxter International Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 91. Baxter International Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Baxter International Inc. Main Business
Table 93. Baxter International Inc. Latest Developments
Table 94. ChemoCentryx Inc. Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 95. ChemoCentryx Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 96. ChemoCentryx Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. ChemoCentryx Inc. Main Business
Table 98. ChemoCentryx Inc. Latest Developments
Table 99. Dimerix Ltd Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 100. Dimerix Ltd Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 101. Dimerix Ltd Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Dimerix Ltd Main Business
Table 103. Dimerix Ltd Latest Developments
Table 104. Medtronic PLC Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 105. Medtronic PLC Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 106. Medtronic PLC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Medtronic PLC Main Business
Table 108. Medtronic PLC Latest Developments
Table 109. Pfizer Inc. Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 110. Pfizer Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 111. Pfizer Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Pfizer Inc. Main Business
Table 113. Pfizer Inc. Latest Developments
Table 114. Mylan N.V. Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 115. Mylan N.V. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 116. Mylan N.V. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Mylan N.V. Main Business
Table 118. Mylan N.V. Latest Developments
Table 119. Amgen Inc. Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 120. Amgen Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 121. Amgen Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Amgen Inc. Main Business
Table 123. Amgen Inc. Latest Developments
Table 124. AstraZeneca plc Basic Information, Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 125. AstraZeneca plc Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Portfolios and Specifications
Table 126. AstraZeneca plc Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. AstraZeneca plc Main Business
Table 128. AstraZeneca plc Latest Developments
List of Figures
Figure 1. Picture of Focal Segmental Glomerulosclerosis (FSGS) Treatment
Figure 2. Focal Segmental Glomerulosclerosis (FSGS) Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Drug Therapy
Figure 10. Product Picture of Dialysis
Figure 11. Product Picture of Kidney Transplant
Figure 12. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Type in 2022
Figure 13. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Type (2018-2023)
Figure 14. Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumed in Primary FSGS
Figure 15. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Primary FSGS (2018-2023) & (K Units)
Figure 16. Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumed in Secondary FSGS
Figure 17. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Secondary FSGS (2018-2023) & (K Units)
Figure 18. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Application (2022)
Figure 19. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Application in 2022
Figure 20. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market by Company in 2022 (K Units)
Figure 21. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Company in 2022
Figure 22. Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Company in 2022
Figure 24. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales 2018-2023 (K Units)
Figure 27. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue 2018-2023 ($ Millions)
Figure 28. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales 2018-2023 (K Units)
Figure 29. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue 2018-2023 ($ Millions)
Figure 30. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales 2018-2023 (K Units)
Figure 31. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue 2018-2023 ($ Millions)
Figure 34. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country in 2022
Figure 35. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Country in 2022
Figure 36. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Type (2018-2023)
Figure 37. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Application (2018-2023)
Figure 38. United States Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Region in 2022
Figure 43. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Regions in 2022
Figure 44. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Type (2018-2023)
Figure 45. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Application (2018-2023)
Figure 46. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country in 2022
Figure 54. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Country in 2022
Figure 55. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Type (2018-2023)
Figure 56. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Application (2018-2023)
Figure 57. Germany Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Application (2018-2023)
Figure 66. Egypt Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Focal Segmental Glomerulosclerosis (FSGS) Treatment in 2022
Figure 72. Manufacturing Process Analysis of Focal Segmental Glomerulosclerosis (FSGS) Treatment
Figure 73. Industry Chain Structure of Focal Segmental Glomerulosclerosis (FSGS) Treatment
Figure 74. Channels of Distribution
Figure 75. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Forecast by Region (2024-2029)
Figure 76. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share Forecast by Application (2024-2029)


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 局所分節性糸球体硬化症（FSGS）治療のグローバル市場予測2023-2029(Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界の巣状分節性糸球体硬化症（FSGS）治療市場2023年：企業・地域・タイプ・用途別分析
  • 限局性結節性糸球体硬化症（FSGS）治療薬のグローバル市場予測2022-2028
  • 限局性糸球体硬化症（FSGS）治療薬のグローバル市場予測2022-2028
  • 世界の巣状分節性糸球体硬化症市場2023-2031：疾患別（原発性巣状分節性糸球体硬化症、続発性巣状分節性糸球体硬化症）、疾患管理別（診断、治療）

    • ◆H&Iグローバルリサーチのお客様（例）◆